Mutual of America Capital Management LLC Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mutual of America Capital Management LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 52,930 shares of the medical device company's stock after selling 4,208 shares during the period. Mutual of America Capital Management LLC's holdings in DexCom were worth $4,116,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter worth $25,000. Private Trust Co. NA increased its position in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter valued at about $38,000. Midwest Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter valued at about $54,000. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom in the third quarter valued at about $57,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of analyst reports. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $99.82.

Remove Ads

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 over the last quarter. Corporate insiders own 0.30% of the company's stock.

DexCom Stock Down 2.1 %

NASDAQ:DXCM traded down $1.67 during mid-day trading on Friday, hitting $77.84. 3,861,055 shares of the company's stock were exchanged, compared to its average volume of 3,717,810. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business has a fifty day moving average price of $84.83 and a 200 day moving average price of $76.99. The company has a market cap of $30.42 billion, a PE ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.